1 Division of Pulmonary Medicine, The First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and Lung, Zhejiang 325000, PR China.
2 Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang 325000, PR China.
Exp Biol Med (Maywood). 2019 Mar;244(3):252-261. doi: 10.1177/1535370219828692. Epub 2019 Feb 2.
In this study, we reported for the first time that FGF21 alleviated hypoxia-induced pulmonary hypertension through attenuation of increased pulmonary arterial pressure, pulmonary arterial remodeling and collagen deposition in vivo, and we confirmed the mutual promotion of FGF21 and PPARγ in hypoxia-induced pulmonary hypertension. Additionally, we found that FGF21 and PPARγ mutually promote each other's expression via the AMPK/PGC-1α pathway and KLB protein in vitro and in vivo. Pulmonary hypertension is a progressive and serious pathological phenomenon with a poor prognosis, and current therapies are highly limited. Our results provide novel insight into potential clinical therapies for pulmonary hypertension and establish the possibility of using this drug combination and potential dosage reductions in clinical settings.
在这项研究中，我们首次报道了 FGF21 通过减轻体内肺动脉高压、肺血管重构和胶原沉积缓解缺氧诱导的肺动脉高压，并证实了 FGF21 和 PPARγ 在缺氧诱导的肺动脉高压中相互促进。此外，我们发现 FGF21 和 PPARγ 通过 AMPK/PGC-1α 通路和 KLB 蛋白在体外和体内相互促进彼此的表达。肺动脉高压是一种进行性和严重的病理现象，预后不良，目前的治疗方法非常有限。我们的研究结果为肺动脉高压的潜在临床治疗提供了新的见解，并为在临床环境中使用这种药物组合和潜在的剂量减少提供了可能性。
